CN113444131A - N-acetylglucosamine compounds, and preparation method and application thereof - Google Patents
N-acetylglucosamine compounds, and preparation method and application thereof Download PDFInfo
- Publication number
- CN113444131A CN113444131A CN202110716707.2A CN202110716707A CN113444131A CN 113444131 A CN113444131 A CN 113444131A CN 202110716707 A CN202110716707 A CN 202110716707A CN 113444131 A CN113444131 A CN 113444131A
- Authority
- CN
- China
- Prior art keywords
- acetylglucosamine
- dichloromethane
- compound
- ethyl acetate
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title abstract description 11
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 title abstract description 6
- 241000894006 Bacteria Species 0.000 claims abstract description 26
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims abstract description 24
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims abstract description 24
- 229950006780 n-acetylglucosamine Drugs 0.000 claims abstract description 24
- -1 N-acetylglucosamine compound Chemical class 0.000 claims abstract description 22
- 241000203233 Aspergillus versicolor Species 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 239000001963 growth medium Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 238000000855 fermentation Methods 0.000 claims abstract description 9
- 230000004151 fermentation Effects 0.000 claims abstract description 9
- 241000607471 Edwardsiella tarda Species 0.000 claims abstract description 8
- 241000607618 Vibrio harveyi Species 0.000 claims abstract description 8
- 241000191938 Micrococcus luteus Species 0.000 claims abstract description 7
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims abstract description 7
- 241000233866 Fungi Species 0.000 claims abstract description 6
- 238000012258 culturing Methods 0.000 claims abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000003208 petroleum Substances 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 238000010898 silica gel chromatography Methods 0.000 claims description 8
- 238000004809 thin layer chromatography Methods 0.000 claims description 8
- 235000002639 sodium chloride Nutrition 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 239000000287 crude extract Substances 0.000 claims description 6
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 6
- 238000009630 liquid culture Methods 0.000 claims description 6
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000002441 reversible effect Effects 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 244000061456 Solanum tuberosum Species 0.000 claims description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 claims description 2
- UAJGYNKUMWOQFQ-UHFFFAOYSA-N dichloromethane;propan-1-ol Chemical compound ClCCl.CCCO UAJGYNKUMWOQFQ-UHFFFAOYSA-N 0.000 claims description 2
- BLEBFDYUDVZRFG-UHFFFAOYSA-N dichloromethane;propan-2-ol Chemical compound ClCCl.CC(C)O BLEBFDYUDVZRFG-UHFFFAOYSA-N 0.000 claims description 2
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- YKWNUSJLICDQEO-UHFFFAOYSA-N ethoxyethane;propan-2-ol Chemical compound CC(C)O.CCOCC YKWNUSJLICDQEO-UHFFFAOYSA-N 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 239000000022 bacteriostatic agent Substances 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical group [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 238000009360 aquaculture Methods 0.000 description 4
- 244000144974 aquaculture Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Abstract
The invention relates to an N-acetylglucosamine compound and a preparation method and application thereof, belonging to the technical field of bacteriostatic agents and microbial medicines, wherein the preparation method comprises the following steps: fermenting and culturing marine fungus Aspergillus versicolor (Aspergillus versicolor) M-7-SW9 in PDB fungus culture medium to obtain fermentation product, extracting and separating the fermentation product to obtain new N-acetylglucosamine compounds. According to the N-acetylglucosamine compound and the preparation method and application thereof, the minimum inhibitory concentration of the compound on aquatic disease bacteria, namely Edwardsiella tarda and Vibrio harveyi is 1.0 microgram/ml, and the compound also has antibacterial activity on aquatic disease bacteria, namely micrococcus luteus and Vibrio parahaemolyticus, and can be used for preparing a medicament for resisting aquatic disease bacteria.
Description
Technical Field
The invention relates to a novel compound and a preparation method and application thereof, in particular to an N-acetylglucosamine compound extracted and separated from a fermentation product of Aspergillus versicolor (Aspergillus versicolor) M-7-SW9, and a preparation method and application thereof, belonging to the technical field of bacteriostatic agents and microbial medicines.
Background
With the expansion of aquaculture scale and the use of a large amount of antibiotics in the aquaculture process, the multiple drug resistance phenomenon of bacteria which are diseases of aquaculture animals is increasingly common, and the use of a large amount of chemical synthetic drugs brings serious pollution to water and soil and causes harm to human and biological health, so that a new idea is provided for solving the problem of bacterial disease control in the current aquaculture process by developing marine organism-derived natural drugs.
The marine fungi can produce secondary metabolites with abundant chemical structure diversity and remarkable biological activity, and are important sources of drug lead compounds; n-acetylglucosamine is a basic composition unit of a plurality of important polysaccharides in biological cells, has a plurality of important physiological functions in organisms, also has the functions of diminishing inflammation, resisting tumors and resisting oxidation, is clinically a medicament for treating osteoarthritis and rheumatoid arthritis, and has wide application in the fields of food, medicine, cosmetics and the like.
According to literature research, the N-acetylglucosamine compounds related to the invention are novel compounds, and are only reported before.
Disclosure of Invention
The purpose of the invention is: in order to overcome the defects in the prior art, an N-acetylglucosamine compound and a preparation method and application thereof are provided.
The technical scheme for solving the technical problems is as follows:
an N-acetylglucosamine compound is shown as formula (I), and has molecular formula C9H15NO5；
A preparation method of N-acetylglucosamine based compounds comprises the following steps:
1) fermenting and culturing marine fungus Aspergillus versicolor (Aspergillus versicolor) M-7-SW9 in PDB fungus culture medium, repeatedly soaking and extracting the fermentation product with organic solvent extract, extracting with ethyl acetate, mixing the extracts, and concentrating to obtain fermented crude extract; the Aspergillus versicolor (Aspergillus versicolor) M-7-SW9 is preserved in China Center for Type Culture Collection (CCTCC) at 25 months 4 in 2021, with the preservation number of CCTCC NO: m2021454;
2) subjecting the crude extract obtained in the step 1) to silica gel column chromatography, performing gradient elution by using an organic solvent elution system, collecting eluent, and detecting the eluent by thin layer chromatography;
3) collecting the eluted components in the step 2), sequentially carrying out reverse phase silica gel column chromatography, gel column chromatography and thin layer chromatography separation and purification, and collecting the components with Rf value of 0.6-0.7 separated and purified by thin layer chromatography to obtain the N-acetylglucosamine compound shown in the formula (I); the volume ratio of the thin-layer chromatography separation and purification developing agent is 2: 1 petroleum ether-ethyl acetate.
Furthermore, the organic solvent extracting solution in the step 1) is one or more of dichloromethane, ethyl acetate, methanol, ethanol, propanol or isopropanol.
Further, the organic solvent elution system in the step 2) is one or more of petroleum ether-ethyl acetate, petroleum ether-ethanol, petroleum ether-propanol, petroleum ether-isopropanol, dichloromethane-ethyl acetate, dichloromethane-methanol, dichloromethane-ethanol, dichloromethane-propanol or dichloromethane-isopropanol; the volume ratio of the organic solvent elution system is 50-0: 1.
further, the volume ratio of the reverse phase silica gel column chromatography eluent in the step 3) is 4-0: 1 water-methanol or water-ethanol; the volume ratio of the gel column chromatography eluent is 2-0: 1 dichloromethane-methanol or dichloromethane-ethanol.
Further, the PDB fungus culture medium formula is as follows: each liter of liquid culture medium contains 200 g of potato powder, 20 g of glucose, 5g of peptone, 3 g of yeast extract and 35 g of sea salt.
Furthermore, the N-acetylglucosamine compound shown in the formula (I) can be used for preparing a novel medicament for resisting aquatic disease bacteria; the bacteria are Edwardsiella tarda, Vibrio harveyi, Micrococcus luteus or Vibrio parahaemolyticus of aquatic disease bacteria.
The invention has the beneficial effects that: the method comprises the steps of culturing and fermenting Aspergillus versicolor (Aspergillus versicolor) M-7-SW9 in a culture medium, extracting and separating the obtained fermentation product to obtain a new N-acetylglucosamine compound, wherein no report of the compound on the inhibition activity of aquatic disease bacteria is found at present, no related medicine is found on the market, the minimum inhibitory concentration of the compound on aquatic disease bacteria, namely Edwardsiella tarda and Vibrio harveyi is 1.0 microgram/ml, and the compound also has the inhibitory activity on aquatic disease bacteria, namely Micrococcus luteus and Vibrio parahaemolyticus, and can be used for preparing the medicine for resisting the aquatic disease bacteria.
Detailed Description
The principles and features of this invention are described below in conjunction with examples which are set forth to illustrate, but are not to be construed to limit the scope of the invention.
The invention obtains the compound N-acetylglucosamine compound as shown in the following examples by culturing and fermenting Aspergillus versicolor M-7-SW9 in a culture medium, extracting and separating the fermentation product, wherein the chemical structure is shown in formula (I):
a seawater sample collected in the Bohai sea area is separated from Aspergillus versicolor (Aspergillus versicolor) M-7-SW9, and is characterized by comprising the following steps: white aerial hyphae grow on the PDA culture medium, gray green spores grow on the PDA culture medium, white aerial hyphae grow on the PDB liquid culture medium in the early stage, and the mycoderm turns dark green in the later stage.
Example 1
A method for preparing an N-acetylglucosamine compound represented by the formula (I):
(1) inoculating marine fungus Aspergillus versicolor (Aspergillus versicolor) M-7-SW9 (with the size of 1.5 cm multiplied by 1.5 cm) growing in a plate culture medium into 250mL of PDB liquid culture medium, fermenting for 7 days at 28 ℃ by using a shaking table (200 revolutions per minute), inoculating the obtained bacterial liquid into 300L of PDB liquid culture medium, fermenting for 7 days by using a 500L fermentation tank, soaking and extracting the fermentation product by using ethanol, repeatedly extracting by using ethyl acetate, combining the extracts, concentrating to obtain a fermented crude extract;
the PDB liquid culture medium comprises the following components in percentage by weight: 200 g of potato powder, 20 g of glucose, 5g of peptone, 3 g of yeast extract and 35 g of sea salt in each liter of water.
(2) The crude extract was subjected to reduced pressure silica gel column chromatography and purified with a gradient of 50: 1 to 1: 1(v/v) petroleum ether-ethyl acetate and a gradient of 50: 1 to 1: 1(v/v) dichloromethane-methanol as a solvent, and collecting dichloromethane-methanol 10: 1(v/v) by reverse phase silica gel column chromatography, eluting with a solvent in the range of 4-0: 1 water-methanol elution; collecting the water-methanol 1: 1(v/v), and further purified by High Performance Liquid Chromatography (HPLC) using water-methanol 1: 1(v/v) is a mobile phase, an absorption peak of 18.5min at the wavelength of 210nm is collected to obtain a purified target compound, and the structure of the purified target compound is identified as shown in a formula (I):
the compound has the following physicochemical and spectral characteristics:
a white powdery solid; specific optical rotation [ alpha ]]20 D-18 (c 0.15, MeOH); hydrogen nuclear magnetic resonance spectrum (solvent is deuterated methanol) deltaH5.69(dd, 4.1, 0.7), 6.33(br s), 4.87(ddd, 3.5, 1.5, 0.7), 3.55(dd, 5.2, 3.5), 3.66(dd, 10.7, 3.5), 3.58(dd, 10.7, 5.2), 2.05(s), 3.33(s); nuclear magnetic resonance carbon spectrum (solvent is deuterated methanol) deltaC 107.5(CH)，133.9(C)，111.7(CH)，86.9(CH)，75.8(CH)，64.4(CH2)，172.0(C)，23.1(CH3)，53.4(CH3) (ii) a High resolution Mass Spectrometry M/z 240.08519[ M + Na ]]+，C9H15NO5Na+The calculated value was 240.084244.
Example 2
Aquatic disease bacteria inhibitor activity:
detecting the activity of the compound shown in the formula (I) against aquatic disease bacteria by using a minimum inhibitory concentration method, and selecting the following 4 aquatic pathogen strains: the antibacterial activity of Edwardsiella tarda, Vibrio harveyi, Micrococcus luteus and Vibrio parahaemolyticus was tested.
(1) Antibacterial activity test (MIC method):
the Minimum Inhibitory Concentration (MIC), i.e. the lowest concentration of drug that is able to inhibit bacterial growth in vitro. Adding medicines with different concentrations into a bacterial suspension of bacteria to be detected in a 96-microporous plate, observing after culturing, and if indicating bacteria grow in a certain hole, indicating that the medicine concentration in the hole can not inhibit the growth of the bacteria, the liquid in the hole is turbid, and the transmittance is obviously reduced; on the contrary, the liquid in the hole is clear, and the transmittance is not reduced obviously. The lowest sample concentration within the well that completely inhibited the growth of the indicator bacteria was the MIC of the compound.
(2) Preparation of the bacterial suspension
The above-mentioned test bacteria were inoculated respectively to a medium (TSB medium for Edwardsiella tarda, LB medium for Vibrio harveyi, Micrococcus luteus and Vibrio parahaemolyticus, respectively) and cultured at 28 ℃ for 24 hours, then 4mL of a sterile 0.85% NaCl solution (8.5g of sodium chloride to a constant volume of 1000mL of water) was aspirated to wash the culture, and the bacteria were gently scraped off with a glass scraper; pipetting the appropriate amount of bacterial suspension into a sterile test tube using a pipette gun, adjusting the bacterial suspension to 0.5 McClod turbidity (equivalent to 1.5X 108CFU/mL) with 0.85% NaCl solution, and further diluting to 5X 105CFU/mL with 0.85% NaCl solution;
the 0.5 mcz turbidity scale was: 0.5mL of 0.048mol/L BaCl2(1.175％w/v BaCl2·2H2O) to 99.5mL of 0.18mol/L (0.36N) H2SO4(1% v/v) with constant agitation to maintain the suspension.
(3) Preparation of samples
About 1mg of a sample to be tested (the N-acetylglucosamine compound obtained above) and a positive control (chloramphenicol) are respectively dissolved in about 100 mu L of DMSO, the mixture is fully mixed to make the final concentration of the mixture 2560 mu g/mL, 50 mu L of sample solution is sucked into another centrifuge tube, and then 50 mu L of DMSO is added to obtain a sample solution with the concentration reduced by half. According to this method, a total of 11 sets of sample solutions (2560, 1280, 640, 320, 160, 80, 40, 20, 10, 5, 2.5. mu.g/mL) with successively halved concentrations were obtained.
(4) Blank control: pure solvent (DMSO) to dissolve the sample to be tested was chosen as a blank.
(5) MIC determination procedure
And 5.1) respectively adding sample solutions with different concentrations after dilution in multiple proportion into a sterile 96-well plate by adopting sterile operation, wherein 5 mu L of sample solution is added into each of the 1 st to 11 th wells, and the 12 th well is not added with a sample and is used as a growth control.
5.2) the indicator suspension corresponding to the turbidity of 0.5 McLeod was diluted 1000-fold in a liquid medium (TSB medium for Edwardsiella tarda, Vibrio harveyi, Micrococcus luteus and Vibrio parahaemolyticus LB medium), and 95. mu.L of the diluted suspension was added to a 96-well plate in order to give final concentrations of 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25 and 0.125. mu.g/mL in the 1 st to 11 th wells in order. After gently shaking and mixing, the 96-well plate is sealed and placed in an incubator at 28 ℃ for bacterial culture for 24 h.
5.3) the absorbance of each well was measured using a microplate reader at a wavelength of 600nm, and the lowest sample concentration at which the growth of the indicator bacteria was completely inhibited in the wells was the MIC of the compound. (Note: it is only meaningful to indicate that the bacteria grows significantly in the negative control wells; the highest concentration of drug inhibiting the growth of the strain should be recorded when a single jump occurs in the experiment; if multiple jumps occur, no results should be reported, and the experiment should be repeated.)
The experimental result shows that the N-acetylglucosamine compound has stronger inhibitory activity on Edwardsiella tarda and Vibrio harveyi respectively, and MIC values are both 1.0 mug/mL.
The experiment results prove that the compound has a strong inhibition effect on aquatic disease bacteria, and can be used for preparing a novel aquatic disease bacteria resistant medicament.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (7)
1. An N-acetylglucosamine compound, characterized in that: the N-acetylglucosamine compound is shown as formula (I), and the molecular formula is C9H15NO5；
2. The method for preparing an N-acetylglucosamine compound according to claim 1, comprising the steps of:
1) fermenting and culturing marine fungus Aspergillus versicolor (Aspergillus versicolor) M-7-SW9 in PDB fungus culture medium, repeatedly soaking and extracting the fermentation product with organic solvent extract, extracting with ethyl acetate, mixing the extracts, and concentrating to obtain fermented crude extract; the Aspergillus versicolor (Aspergillus versicolor) M-7-SW9 is preserved in China Center for Type Culture Collection (CCTCC) at 25 months 4 in 2021, with the preservation number of CCTCC NO: m2021454;
2) subjecting the crude extract obtained in the step 1) to silica gel column chromatography, performing gradient elution by using an organic solvent elution system, collecting eluent, and detecting the eluent by thin layer chromatography;
3) collecting the eluted components in the step 2), sequentially carrying out reverse phase silica gel column chromatography, gel column chromatography and thin layer chromatography separation and purification, and collecting the components with Rf value of 0.6-0.7 separated and purified by thin layer chromatography to obtain the N-acetylglucosamine compound shown in the formula (I); the volume ratio of the thin-layer chromatography separation and purification developing agent is 2: 1 petroleum ether-ethyl acetate.
3. The method for producing an N-acetylglucosamine compound according to claim 2, wherein: the organic solvent extracting solution in the step 1) is one or more of dichloromethane, ethyl acetate, methanol, ethanol, propanol or isopropanol.
4. The method for producing an N-acetylglucosamine compound according to claim 2, wherein: the organic solvent elution system in the step 2) is one or more of petroleum ether-ethyl acetate, petroleum ether-ethanol, petroleum ether-propanol, petroleum ether-isopropanol, dichloromethane-ethyl acetate, dichloromethane-methanol, dichloromethane-ethanol, dichloromethane-propanol or dichloromethane-isopropanol; the volume ratio of the organic solvent elution system is 50-0: 1.
5. the method for producing an N-acetylglucosamine compound according to claim 2, wherein: the volume ratio of the reverse phase silica gel column chromatography eluent in the step 3) is 4-0: 1 water-methanol or water-ethanol; the volume ratio of the gel column chromatography eluent is 2-0: 1 dichloromethane-methanol or dichloromethane-ethanol.
6. The method for producing an N-acetylglucosamine compound according to claim 2, wherein: the PDB fungus culture medium comprises the following components in percentage by weight: each liter of liquid culture medium contains 200 g of potato powder, 20 g of glucose, 5g of peptone, 3 g of yeast extract and 35 g of sea salt.
7. The use of the N-acetylglucosamine compound according to claim 1, wherein: the N-acetylglucosamine compound shown in the formula (I) can be used for preparing novel medicines for resisting aquatic disease bacteria; the bacteria are Edwardsiella tarda, Vibrio harveyi, Micrococcus luteus or Vibrio parahaemolyticus of aquatic disease bacteria.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110716707.2A CN113444131B (en) | 2021-06-24 | 2021-06-24 | N-acetylglucosamine compounds, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110716707.2A CN113444131B (en) | 2021-06-24 | 2021-06-24 | N-acetylglucosamine compounds, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113444131A true CN113444131A (en) | 2021-09-28 |
| CN113444131B CN113444131B (en) | 2022-10-21 |
Family
ID=77813331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110716707.2A Active CN113444131B (en) | 2021-06-24 | 2021-06-24 | N-acetylglucosamine compounds, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113444131B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114957034A (en) * | 2022-06-28 | 2022-08-30 | 广西中医药大学 | Amino acid derivative and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4108071A1 (en) * | 1991-03-13 | 1992-09-17 | Desowag Materialschutz Gmbh | AGENT OR CONCENTRATE FOR THE PRESERVATION OF WOOD AND WOOD MATERIALS AGAINST WOOD-DESTRUCTING AND / OR WOOD-DEGRADING AND / OR CELLULOSE-DEGRADING ORGANISMS |
| WO2009143455A2 (en) * | 2008-05-22 | 2009-11-26 | Microbia, Inc. | Engineering resistance to aliphatic alcohols |
| US20110206721A1 (en) * | 2010-02-19 | 2011-08-25 | Vijaya Nair | Fermented soy nutritional supplements including mushroom components |
| CN107805188A (en) * | 2017-09-14 | 2018-03-16 | 宁波大学 | A kind of biphenyl compound and its production and use |
| CN108337892A (en) * | 2015-01-30 | 2018-07-27 | 埃沃尔瓦公司 | Steviol glycoside is produced in the recombination host |
| CN108779094A (en) * | 2015-12-30 | 2018-11-09 | Vps-3有限公司 | metal enzyme inhibitor compound |
| CN109195457A (en) * | 2016-04-13 | 2019-01-11 | 埃沃尔瓦公司 | Steviol glycoside is generated in the recombination host |
| CN110981935A (en) * | 2019-12-17 | 2020-04-10 | 云南民族大学 | Cyclic tetrapeptide compound and preparation method thereof |
-
2021
- 2021-06-24 CN CN202110716707.2A patent/CN113444131B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4108071A1 (en) * | 1991-03-13 | 1992-09-17 | Desowag Materialschutz Gmbh | AGENT OR CONCENTRATE FOR THE PRESERVATION OF WOOD AND WOOD MATERIALS AGAINST WOOD-DESTRUCTING AND / OR WOOD-DEGRADING AND / OR CELLULOSE-DEGRADING ORGANISMS |
| WO2009143455A2 (en) * | 2008-05-22 | 2009-11-26 | Microbia, Inc. | Engineering resistance to aliphatic alcohols |
| US20110206721A1 (en) * | 2010-02-19 | 2011-08-25 | Vijaya Nair | Fermented soy nutritional supplements including mushroom components |
| CN108337892A (en) * | 2015-01-30 | 2018-07-27 | 埃沃尔瓦公司 | Steviol glycoside is produced in the recombination host |
| CN108779094A (en) * | 2015-12-30 | 2018-11-09 | Vps-3有限公司 | metal enzyme inhibitor compound |
| CN109195457A (en) * | 2016-04-13 | 2019-01-11 | 埃沃尔瓦公司 | Steviol glycoside is generated in the recombination host |
| CN107805188A (en) * | 2017-09-14 | 2018-03-16 | 宁波大学 | A kind of biphenyl compound and its production and use |
| CN110981935A (en) * | 2019-12-17 | 2020-04-10 | 云南民族大学 | Cyclic tetrapeptide compound and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| JING CHEN ET AL: ""Two new N-acetyl-ᴅ-glucosamine derivatives from the medical algae-derived endophytic fungus Penicillium chrysogenum"", 《NATURAL PRODUCT RESEARCH》 * |
| PAVLA BOJAROVÁ ET AL.: ""Selective β-N-acetylhexosaminidase from Aspergillus versicolor—a tool for producing bioactive carbohydrates"", 《APPLIED MICROBIOLOGY AND BIOTECHNOLOGY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114957034A (en) * | 2022-06-28 | 2022-08-30 | 广西中医药大学 | Amino acid derivative and preparation method and application thereof |
| CN114957034B (en) * | 2022-06-28 | 2023-06-23 | 广西中医药大学 | Amino acid derivative and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113444131B (en) | 2022-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104277982B (en) | Tricyclic sesquiterpenoid compound as well as preparation method and applications thereof | |
| EP3029147A1 (en) | A method of semi-solid state fermentation for producing surfactin from a mutant strain of bacillus subtilis subsp | |
| CN113444131B (en) | N-acetylglucosamine compounds, and preparation method and application thereof | |
| CN110117546B (en) | Naphthoquinone compound derived from marine fungi and anti-inflammatory application thereof | |
| CN111072670B (en) | Diketopiperazine compound and preparation method and application thereof | |
| CN113621526B (en) | Marine fungus aspergillus versicolor M-7-SW9, mixed source terpenoid and extraction method and application thereof | |
| CN108383707A (en) | A kind of daucane sesquiterpenoids and its preparation and application | |
| CN112111409B (en) | Penicillium oxalicum and application thereof | |
| CN108503534B (en) | Extraction method and application of p-hydroxybenzoic acid | |
| CN108863749B (en) | Diterpenoid-reducing compound and preparation method and application thereof | |
| CN108794502B (en) | Trichothecene compound and preparation method and application thereof | |
| CN102786528A (en) | Polyoxybiotic alkali compound as well as preparation method and application thereof | |
| CN108586218B (en) | Chloro cyclopentenone compound and preparation and application thereof | |
| CN107973803B (en) | Seven-membered lactonofuran derivative and preparation method and application thereof | |
| CN110642823A (en) | Pyran derivative and preparation method and application thereof | |
| CN112107602B (en) | A pair of twin-nitrogen containing alkaloid enantiomers, preparation and application thereof | |
| CN112694406B (en) | Preparation method and application of two dimeric hexyl itaconic acid derivatives | |
| CN115247131B (en) | Trichoderma atroviride and metabolite and application thereof | |
| CN112961170B (en) | Sponge source actinomycetes and preparation method and application of sulfur-containing alkaloid produced by sponge source actinomycetes | |
| CN113173904B (en) | Novel bacteriostatic compounds and aspergillus for preparing the same | |
| CN109467546B (en) | Thio-macrolide compound, preparation method thereof and application of thio-macrolide compound in resisting aquatic disease bacterium activity | |
| CN109265515B (en) | Cyclopeptide compound and preparation method and application thereof | |
| CN111635316B (en) | Chlorine-containing sesquiterpene derivative and preparation and application thereof | |
| CN109251145B (en) | Phthalate, and preparation method, strain and application thereof | |
| CN107629070B (en) | A kind of carbamate compound and its preparation and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231130 Address after: No. 2988 Airport West Road, High tech Zone, Jinan City, Shandong Province, 250101 Patentee after: Jinan Baiming Biological Pharmaceutical Co.,Ltd. Address before: 264001 No.184, Hongqi Middle Road, Zhifu District, Yantai City, Shandong Province Patentee before: LUDONG University |